| Old Articles: <Older 8191-8200 Newer> |
|---|
 |
The Motley Fool
January 4, 2012
Brian Orelli |
Mark Your Calendars, Biotech Investors Cell Therapeutics' advisory panel meet ought to be entertaining.   |
The Motley Fool
January 4, 2012
Brian Orelli |
This Biotech's Obese To-Do List Is Done Arena resubmits lorcaserin for FDA approval. |
The Motley Fool
January 4, 2012
Sean Williams |
2012 Preview: K-V Pharmaceuticals Conserving cash will be a primary objective for K-V in 2012. |
The Motley Fool
January 4, 2012
Rebecca Lipman |
Biotech Ideas: Top Biotech Stocks with Bullish Institutional Trends "Smart money" investors are feeling bullish about these biotech companies: Amyris... VIVUS... InterMune... Savient Pharmaceuticals... Bacterin International... Seattle Generics... Oncothyreon... |
The Motley Fool
January 3, 2012
Alex Planes |
Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on. |
The Motley Fool
January 3, 2012
Brian Orelli |
High Expectations Trump Solid Results AVEO slumps despite solid results for tivozanib. |
The Motley Fool
January 3, 2012
Seth Jayson |
Neogen Increases Sales but Misses Revenue Estimate Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Neogen is outperform, with an average price target of $39.60. |
The Motley Fool
January 2, 2012
Anders Bylund |
What Will Elan Do for an Encore? 2011 was a great year for the Irish biotech. Here's how that momentum carries through into 2012. |
Chemistry World
January 2012 |
Column: In the pipeline Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about |
Chemistry World
January 2012 |
Rising interest in compound bank David Fox argues for the creation of a centralized repository for small molecules to harness research efforts in drug discovery |
| <Older 8191-8200 Newer> Return to current articles. |
